

Matteo Lambertini, MD PhD

✉ matteo.lambertini@unige.it

Sex Male | [Date of birth](#) 24/09/1985 | [Nationality](#) Italian
[Mother tongue](#) Italian | [Other languages](#) English (written and spoken)



WORK EXPERIENCES

- [February 2022-Present](#): Associate Professor, Consultant in Medical Oncology, Department of Medical Oncology, IRCCS Ospedale Policlinico San Martino-University of Genova, Genova (Italy)
- [January 2019-January 2022](#): Assistant Professor, Consultant in Medical Oncology, Department of Medical Oncology, IRCCS Ospedale Policlinico San Martino-University of Genova, Genova (Italy)
- [January 2016-December 2018](#): Clinical Research Associate-ESMO Translational Research Fellow, Medical Oncology Department, Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Brussels (Belgium)
- [June 2011-June 2016](#): Specialty in Medical Oncology at the Medical Oncology Department, IRCCS AOU San Martino-IST, Genova (Italy)
- [January 2015-February 2015](#): Visiting Researcher, Medical Oncology Department, Thomas Jefferson University, Philadelphia, PA
- [July 2014-December 2014](#): Visiting Researcher, Medical Oncology Department, Adult Survivorship Programme, Dana-Farber Cancer Institute, Boston, MA
- [August 2013-September 2013](#): ESMO Clinical Unit Visit, Department of Medicine, BrEAST Data Centre, Institut Jules Bordet, Brussels (Belgium)
- [December 2010-June 2011](#): Contractor at the S.S. Sviluppo Terapie Innovative, IST - National Cancer Institute, Genova (Italy)
- [October 2008-November 2010](#): Trainee at the Medical Oncology Division, IST - National Cancer Institute, Genova (Italy)

EDUCATION AND TRAINING

- [October 2016-November 2018](#): PhD Programme, Université Libre de Bruxelles (U.L.B.), Brussels (Belgium)
- [June 2011-June 2016](#): School of specialization in Medical Oncology at University of Genova, Genova (Italy); voting 50/50 cum laude
- [February 10, 2011](#): Qualification at University of Genova, Genova (Italy); voting 270/270
- [September 2004-July 2010](#): Bachelor in Medicine and Surgery at University of Genova, Genova (Italy); voting 110/110 cum laude
- [September 1999-July 2004](#): Scientific Licence at Liceo Scientifico Statale "San Giuseppe Calasanzio", Carcare (Savona) Italy; voting 100/100

PUBLICATIONS

- 267 publications** in peer-review journals (**75 as first author**); selected 5 publications:
- **Lambertini M** et al. "Pregnancy after breast cancer: a systematic review and meta-analysis". *J Clin Oncol.* 2021;39(29):3293-305
 - **Lambertini M** et al. "Pregnancy after breast cancer in patients with germline *BRCA* mutations". *J Clin Oncol.* 2020;38(26):3012-23
 - **Lambertini M** et al. "Gonadotropin-releasing hormone agonists during chemotherapy for preservation of ovarian function and fertility in premenopausal patients with early breast cancer: a systematic review and meta-analysis of individual patient-level data". *J Clin Oncol.* 2018;36(19):1981-90
 - **Lambertini M** et al. "Reproductive potential and performance of fertility preservation strategies in *BRCA*-mutated breast cancer patients". *Ann Oncol.* 2018;29:237-243
 - **Lambertini M** et al. "Ovarian suppression with triptorelin during adjuvant breast cancer chemotherapy and long-term ovarian function, pregnancies, and disease-free survival: a randomized clinical trial". *JAMA.* 2015;314:2632-40

**ORAL ABSTRACT
PRESENTATION**

80 abstracts at International conferences (**26 as first author**) and **46 abstracts** at National conferences (**7 as first author**). Selected 5 oral abstract presentations:

- “Safety of pregnancy following breast cancer (BC) in patients (pts) carrying a *BRCA* mutation (*mBRCA*): results of an international cohort study”. 2019 ASCO Annual Meeting, 3 June 2019, Chicago, IL (USA)
- “Pooled analysis of five randomized trials investigating temporary ovarian suppression with gonadotropin-releasing hormone analogs during chemotherapy as a strategy to preserve ovarian function and fertility in premenopausal early breast cancer patients”. 2017 SABCS, 7 December 2017, San Antonio, TX (USA)
- “Reproductive potential and performance of fertility-preserving procedures in *BRCA* mutation-positive breast cancer patients”. ESMO 2017 Congress, 9 September 2017, Madrid (Spain)
- “Dose-dense adjuvant chemotherapy, treatment-induced amenorrhea and overall survival in premenopausal breast cancer patients: a pooled analysis of the MIG1 and GIM2 phase III studies”. European Breast Cancer Conference (EBCC)-10, 10 March 2016, Amsterdam (The Netherlands)
- “Long-term outcome results of the phase III PROMISE-GIM6 study evaluating the role of LHRH analog during chemotherapy as a strategy to reduce ovarian failure in early breast cancer patients”. 2014 ASCO Breast Cancer Symposium, 4-7 September 2014, San Francisco, CA (USA)

HONORS AND AWARDS

- Current Oncology 2021 Young Investigator Award
- 2019 Conquer Cancer Foundation of ASCO Merit Award at the 2019 ASCO Annual Meeting in Chicago, IL (USA)
- 2018 Conquer Cancer Foundation of ASCO Merit Award at the 2018 ASCO Annual Meeting in Chicago, IL (USA)
- 2017 SABCS Clinical Scholar Award at the San Antonio Breast Cancer Symposium, San Antonio, TX (USA)
- 2017 Conquer Cancer Foundation of ASCO Merit Award at the 2017 ASCO Annual Meeting in Chicago, IL (USA)
- ESMO Translational Research Fellowship - Institut Jules Bordet, from August 2016 onwards, Brussels (Belgium)
- “Marco Venturini” Award Lecture - XVIII Italian National Oncology AIOM Conference, 28-30 October 2016 in Rome (Italy)
- Best publication by a young oncologist - Annual National Congress of the AIOM Young Oncologist Committee, 28-30 October 2016 in Perugia (Italy)
- Best abstract - oral presentation at the “ESO (European School of Oncology) BCY2 - 2nd Breast Cancer in Young Women Conference”, 4-5 November 2014, Dublin (Ireland)
- Best oral presentation at the XVI Italian National Oncology Conference, 24-26 October 2014 in Rome (Italy)
- 2014 Conquer Cancer Foundation of ASCO Merit Award at the 2014 ASCO Breast Cancer Symposium in San Francisco, CA (USA)
- 2014 Conquer Cancer Foundation of ASCO Merit Award at the 2014 ASCO Annual Meeting in Chicago, IL (USA)
- ESMO Clinical Unit Visit Fellowship - Institut Jules Bordet, from 19 August 2013 to 27 September 2013, Brussels (Belgium)
- ESMO Translational Research Unit Visit Fellowship (“Lost in Translation: How to find your way”) - The Christie NHS Foundation Trust, 21-23 November 2012, Manchester (United Kingdom)
- Honorable mention - poster presentation at the “ESO BCY1 - Breast Cancer in Young Women Conference”, 8-10 November 2012, Dublin (Ireland)

**MEMBERSHIP
OTHER ACTIVE ROLES**



- European Society for Medical Oncology (ESMO) since October 2011
- American Society of Clinical Oncology (ASCO) since January 2012
- Associazione Italiana di Oncologia Medica (AIOM) since January 2012
- European Society of Human Reproduction and Embryology (ESHRE) since January 2018
- ESMO Leaders Generation Programme graduate since June 2017
- Regional IRB (Comitato Etico Regionale Liguria) since January 2021
- AIOM National Council (consiglio direttivo nazionale) since October 2021
- Chair of the ESMO Young Oncologists Committee (YOC) since January 2023

February 8, 2023